Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10567897 | 0.81 | MEN1 (0.69) | MEN1KMT2ATSHRPOLBMT-CO2 | |
| SCHEMBL22571115 | 0.78 | ALDH1A1 (0.59) | MEN1KMT2ATSHRPOLBALDH1A1 | |
| SCHEMBL8636371 | 0.78 | ALDH1A1 (0.59) | MEN1KMT2ATSHRPOLBALDH1A1 | |
| SCHEMBL27707089 | 0.75 | MEN1 (0.62) | MEN1KMT2ATSHRPOLBMT-CO2 | |
| SCHEMBL27707082 | 0.73 | ALDH1A1 (0.61) | MEN1KMT2ATSHRPOLBALDH1A1 | |
| SCHEMBL9354236 | 0.72 | ALDH1A1 (0.59) | MEN1KMT2ATSHRPOLBALDH1A1 | |
| SCHEMBL20846699 | 0.72 | ALDH1A1 (0.59) | MEN1KMT2ATSHRPOLBALDH1A1 | |
| SCHEMBL13484190 | 0.72 | ALDH1A1 (0.62) | ALDH1A1MAPTLMNAGAA | |
| SCHEMBL27687819 | 0.71 | MEN1 (0.78) | MEN1KMT2ATSHRPOLBALDH1A1 | |
| SCHEMBL27687818 | 0.70 | LMNA (0.64) | MEN1KMT2ATSHRPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |